STIC Biotechnology Systems Branch

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number:	101205 1082E)
Source:	PCT	
Date Processed by STIC:	7-7-05	

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.
PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

1.- [-

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION AND PATENTIN SOFTWARE QUESTIONS, PLEASE CONTACT MARK SPENCER, TELEPHONE: 571-272-2510; FAX: 571-273-0221

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 4.2.2 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

http://www.uspto.gov/web/offices/pac/checker/chkrnote.htm

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail. Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom. Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

- 1. EFS-Bio (http://www.uspto.gov/ebc/efs/downloads/documents.htm, EFS Submission User Manual ePAVE)
- 2. U.S. Postal Service: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450
- 3. Hand Carry, Federal Express, United Parcel Service, or other delivery service (EFFECTIVE 01/14/05): U.S. Patent and Trademark Office, Mail Stop Sequence, Customer Window, Randolph Building, 401 Dulany Street, Alexandria, VA 22314

Revised 01/24/05

Raw Sequence Listing Error Summary

ERROR DETECTED	SUGGESTED CORRECTION SERIAL NUMBER: 101502, 0854		
ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE			
IWrapped Nucleics Wrapped Aminos	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3; this will prevent "wrapping."		
2Invalid Line Length	The rules require that a line not exceed 72 characters in length. This includes white spaces.		
3Misaligned Amino Numbering	The numbering under each 5 th amino acid is misaligned. Do not use tab codes between numbers; use space characters , instead.		
4Non-ASCII	The submitted file was not saved in ASCII(DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text.		
5Variable Length	Sequence(s) contain n's or Xaa's representing more than one residue. Per Sequence Rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the <220>-<223> section that some may be missing.		
6Patentln 2.0 "bug"	A "bug" in Patentln version 2.0 has caused the <220>-<223> section to be missing from amino acid sequences(s) Normally, Patentln would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies to the mandatory <220>-<223> sections for Artificial or Unknown sequences.		
7Skipped Sequences (OLD RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) (i) SEQUENCE CHARACTERISTICS: (Do not insert any subheadings under this heading) (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: (insert SEQ ID NO where "X" is shown) This sequence is intentionally skipped		
	Please also adjust the "(ii) NUMBER OF SEQUENCES:" response to include the skipped sequences.		
8Skipped Sequences (NEW RULES)	Sequence(s) missing. If intentional, please insert the following lines for each skipped sequence. <210> sequence id number <400> sequence id number 000		
9Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Per 1.823 of Sequence Rules, use of <220>-<223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.		
10Invalid 213> Response	Per 1.823 of Sequence Rules, the only valid <213> responses are: Unknown, Artificial Sequence, or scientific name (Genus/species). <220>-<223> section is required when <213> response is Unknown or is Artificial Sequence		
Use of <220>	Use of <220> to <223> is MANDATORY if <213> "Organism" response is "Artificial Sequence" or "Unknown." Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 06/01/1998, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of Sequence Rules)		
PatentIn 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other manual means to copy file to floppy disk.		
13 Misuse of n/Xaa	"n" can only represent a single <u>nucleotide</u> ; "Xaa" can only represent a single <u>amino acid</u>		

AMC - Biotechnology Systems Branch - 09/09/2003



PCT

DATE: 07/07/2005 RAW SEQUENCE LISTING PATENT APPLICATION: US/10/502,085A TIME: 13:46:34 Input Set : A:\sequence listing.txt Output Set: N:\CRF4\07072005\J502085A.raw 3 <110> APPLICANT: BIOMIRA INC. et al. 5 <120> TITLE OF INVENTION: IMMUNOSTIMULATORY, COVALENTLY LIPIDATED OIGONUCLEOTIDES 7 <130> FILE REFERENCE: JIANG=4A PCT C--> 9 <140> CURRENT APPLICATION NUMBER: US/10/502,085A C--> 10 <141> CURRENT FILING DATE: 2004-07-22 12 <150> PRIOR APPLICATION NUMBER: 60/353,195 Does Not Comply 13 <151> PRIOR FILING DATE: 2002-02-04 Corrected Diskette Mender 15 <160> NUMBER OF SEQ ID NOS: 12 17 <170> SOFTWARE: PatentIn version 3.3 19 <210> SEQ ID NO: 1 20 <211> LENGTH: 10 21 <212> TYPE: DNA 22 <213> ORGANISM: (Artificial Sequence 24 <220> FEATURE: 25 <223> OTHER INFORMATION: 128H described in Cheng et al. USP 5,646,126 27 <400> SEQUENCE: 1 28 cacacgtgtg 31 <210> SEQ ID NO: 2 32 <211> LENGTH: 25 33 <212> TYPE: PRT 34 <213> ORGANISM: Artificial Sequence 36 <220> FEATURE: 37 <223> OTHER INFORMATION: Synthesized peptide shown in Fig. 17 BP1-148 39 <400> SEQUENCE: 2 41 Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Asp Thr Arg 42 1 5 45 Pro Ala Pro Gly Ser Thr Ala Pro Pro 20 49 <210> SEQ ID NO: 3 50 <211> LENGTH: 20 51 <212> TYPE: DNA 52 <213> ORGANISM: Artificial Sequence 54 <220> FEATURE: 55 <223> OTHER INFORMATION: Synthesizable activating sequence, shown in Fig. 1 57 <400> SEQUENCE: 3 20 58 ggtgcatcga tgcaggggg 61 <210> SEQ ID NO: 4 62 <211> LENGTH: 10 63 <212> TYPE: PRT 64 <213> ORGANISM: Leishmani major 66 <400> SEQUENCE: 4

69 1

68 Glu Ala Glu Glu Ala Ala Arg Leu Gln Ala

RAW SEQUENCE LISTING DATE: 07/07/2005 PATENT APPLICATION: US/10/502,085A TIME: 13:46:34

Input Set : A:\sequence listing.txt
Output Set: N:\CRF4\07072005\J502085A.raw

72 <210> SEQ ID NO: 5 73 <211> LENGTH: 25 74 <212> TYPE: PRT 75 <213> ORGANISM: Artificial Sequence 77 <220> FEATURE: 78 <223> OTHER INFORMATION: MUC1 repeat consensus sequence 80 <400> SEQUENCE: 5 82 Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala Gln Thr Ala His Gly Val . 10 86 Thr Ser Ala Pro Asp Glu Thr Ser Arg 20 90 <210> SEQ ID NO: 6 91 <211> LENGTH: 12 92 <212> TYPE: PRT 93 <213> ORGANISM: Artificial Sequence 95 <220> FEATURE: 96 <223> OTHER INFORMATION: MUC1 fragment 98 <400> SEQUENCE: 6 100 Pro Gly Ser Thr Ala Pro Pro Ala His Gly Val Thr 101 1 104 <210> SEQ ID NO: 7 105 <211> LENGTH: 9 106 <212> TYPE: PRT 107 <213> ORGANISM: Artificial Sequence 109 <220> FEATURE: 110 <223> OTHER INFORMATION: MUC1 fragment 112 <400> SEQUENCE: 7 114 Thr Leu Ala Pro Ala Thr Glu Pro Ala 115 1 118 <210> SEQ ID NO: 8 119 <211> LENGTH: 9 120 <212> TYPE: PRT 121 <213> ORGANISM: Artificial Sequence 123 <220> FEATURE: 124 <223> OTHER INFORMATION: MUC1 fragment 126 <400> SEQUENCE: 8 128 Ala Leu Gly Ser Thr Ala Pro Pro Val 129 1 132 <210> SEQ ID NO: 9 133 <211> LENGTH: 9 134 <212> TYPE: PRT 135 <213> ORGANISM: Artificial Sequence 137 <220> FEATURE: 138 <223> OTHER INFORMATION: MUC1 fragment 140 <400> SEQUENCE: 9 142 Phe Leu Ser Phe His Ile Ser Asn Leu 143 1 146 <210> SEQ ID NO: 10

147 <211> LENGTH: 20

RAW SEQUENCE LISTING

PATENT APPLICATION: US/10/502,085A

DATE: 07/07/2005 TIME: 13:46:34

Input Set : A:\sequence listing.txt
Output Set: N:\CRF4\07072005\J502085A.raw

- 148 <212> TYPE: PRT
- 149 <213> ORGANISM: Artificial Sequence
- 151 <220> FEATURE:
- 152 <223> OTHER INFORMATION: MUC1 repeat
- 154 <400> SEQUENCE: 10
- 156 Gly Val Thr Ser Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala
- 157 1 5 10 15
- 160 Pro Pro Ala His
- 161 20
- 164 <210> SEQ ID NO: 11
- 165 <211> LENGTH: 28
- 166 <212> TYPE: PRT
- 167 <213> ORGANISM: Artificial Sequence
- 169 <220> FEATURE:
- 170 <223> OTHER INFORMATION: Synthesized peptide shown in Fig. 17 as intermediate
- 173 <220> FEATURE:
- 174 <221> NAME/KEY: misc_feature
- 175 <222> LOCATION: (27)..(27)
- 176 <223> OTHER INFORMATION: Lys is modified by a palmitoyl group
- 178 <400> SEQUENCE: 11
- 180 Ser Thr Ala Pro Pro Ala His Gly Val Thr Ser Ala Pro Pro Asp Thr
- 181 1 5 10
- 184 Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Lys Gly
- 185 20
- 188 <210> SEQ ID NO: 12
- 189 <211> LENGTH: 12
- 190 <212> TYPE: PRT
- 191 <213> ORGANISM: Plasmodium falciparum
- 193 <400> SEQUENCE: 12
- 195 Asn Ala Asn Pro Asn Ala Asn Pro Asn Ala Asn Pro
- 196 1 5 1

VERIFICATION SUMMARY

PATENT APPLICATION: US/10/502,085A

DATE: 07/07/2005 TIME: 13:46:35

Input Set : A:\sequence listing.txt

Output Set: N:\CRF4\07072005\J502085A.raw

L:9 M:270 C: Current Application Number differs, Replaced Current Application Number L:10 M:271 C: Current Filing Date differs, Replaced Current Filing Date